Pyxis Oncology Statistics

Total Valuation

Pyxis Oncology has a market cap or net worth of $76.12 million. The enterprise value is -$48.16 million.

Market Cap	76.12M
Enterprise Value	-48.16M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025, before market open.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Pyxis Oncology has 59.47 million shares outstanding. The number of shares has increased by 44.74% in one year.

Current Share Class	59.47M
Shares Outstanding	59.47M
Shares Change (YoY)	+44.74%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	6.47%
Owned by Institutions (%)	30.17%
Float	39.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.30
Forward PS	n/a
PB Ratio	0.50
P/TBV Ratio	0.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.33, with a Debt / Equity ratio of 0.13.

Current Ratio	7.33
Quick Ratio	7.13
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -39.34% and return on invested capital (ROIC) is -24.11%.

Return on Equity (ROE)	-39.34%
Return on Assets (ROA)	-21.06%
Return on Invested Capital (ROIC)	-24.11%
Return on Capital Employed (ROCE)	-36.78%
Revenue Per Employee	$322,920
Profits Per Employee	-$1.15M
Employee Count	50
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.93% in the last 52 weeks. The beta is 1.07, so Pyxis Oncology's price volatility has been similar to the market average.

Beta (5Y)	1.07
52-Week Price Change	-73.93%
50-Day Moving Average	1.54
200-Day Moving Average	3.02
Relative Strength Index (RSI)	32.91
Average Volume (20 Days)	551,237

Short Selling Information

The latest short interest is 7.00 million, so 11.78% of the outstanding shares have been sold short.

Short Interest	7.00M
Short Previous Month	7.42M
Short % of Shares Out	11.78%
Short % of Float	17.85%
Short Ratio (days to cover)	11.41

Income Statement

In the last 12 months, Pyxis Oncology had revenue of $16.15 million and -$57.36 million in losses. Loss per share was -$1.06.

Revenue	16.15M
Gross Profit	15.67M
Operating Income	-64.37M
Pretax Income	-57.80M
Net Income	-57.36M
EBITDA	-61.25M
EBIT	-64.37M
Loss Per Share	-$1.06

Full Income Statement

Balance Sheet

The company has $144.82 million in cash and $20.54 million in debt, giving a net cash position of $124.28 million or $2.09 per share.

Cash & Cash Equivalents	144.82M
Total Debt	20.54M
Net Cash	124.28M
Net Cash Per Share	$2.09
Equity (Book Value)	153.68M
Book Value Per Share	2.59
Working Capital	128.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$53.64 million and capital expenditures -$237,000, giving a free cash flow of -$53.87 million.

Operating Cash Flow	-53.64M
Capital Expenditures	-237,000
Free Cash Flow	-53.87M
FCF Per Share	-$0.91

Full Cash Flow Statement

Margins

Gross Margin	97.06%
Operating Margin	-398.67%
Pretax Margin	-355.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Pyxis Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-44.74%
Shareholder Yield	-44.74%
Earnings Yield	-75.35%
FCF Yield	-70.78%

Analyst Forecast

The average price target for Pyxis Oncology is $9.20, which is 618.75% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.20
Price Target Difference	618.75%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-10.13%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pyxis Oncology has an Altman Z-Score of 0.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.03
Piotroski F-Score	2